Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients

Lumacaftor/Ivacaftor (LUM-IVA), a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector-potentiator combination, improves lung function and reduces pulmonary exacerbations (PEx) in F508d...

Source: BMC Clinical Pharmacology - October 20, 2022 Category: Drugs & Pharmacology Authors: Karin Yaacoby-Bianu, Zeev Schnapp, Ilana Koren, Anat Ilivitzki, Mohamed Khatib, Nadeem Shorbaji, Michal Shteinberg and Galit Livnat Tags: Research Source Type: research